title: New monoclonal antibodies for the treatment of acute lymphoblastic leukemia.
abstract: Monoclonal antibodies represent a major advance in treatment of acute lymphoblastic leukemia (ALL). Targeted delivery of these agents based on leukemic cell-surface receptor recognition, improves efficacy and minimizes off-target toxicity. The antigens CD19, CD20, CD22 and CD52, are the most common antigens to which monoclonal antibodies in B-cell ALL have been directed. Rituximab, an anti-CD20 antibody, in combination with conventional chemotherapy has been shown to improve survival in newly diagnosed CD20 positive B-cell ALL. Blinatumomab, a bispecific T-cell engager, as monotherapy in relapsed and refractory B-cell ALL resulted in prolonged relapse free survival. Inotuzumab ozogamicin, an anti-CD22 antibody, alone and in combination with chemotherapy has been promising in relapsed and refractory B-cell ALL. The effectiveness and safety of several newer monoclonal antibodies including ofatumumab, obinutuzumab, epratuzumab, denintuzumab mafodotin and moxetumomab pasudotox as single agents or in combination with a chemotherapeutic back bone are currently under investigation.
authors: Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, United States.
authors: Nosha
authors: N
authors: Farhadfar
authors: Division of Hematology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, United States. Electronic address: litzow.mark@mayo.edu.
authors: Mark R
authors: MR
authors: Litzow
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology; D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D000944:Antigens, Differentiation, B-Lymphocyte; D000970:Antineoplastic Agents
keywords: Acute lymphoblastic leukemia (ALL); Monoclonal antibodies; Targeted therapy